Breaking down protein degradation mechanisms in cardiac muscle

Trends in Molecular Medicine

Volumn 19, Issue 4, 2013, Pages 239-249

  Lyon, Robert C ^a   Lange, Stephan ^a   Sheikh, Farah ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cardiac disease; Cardiac muscle; Lysosomal autophagy; Protein turnover; Ubiquitin proteasome

Indexed keywords

ALPHA B CRYSTALLIN; BAFILOMYCIN A1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CONNEXIN 43; INTEGRIN; LACTACYSTIN BETA LACTONE; LEUPEPTIN; MEMBRANE PROTEIN; NBR1 PROTEIN; PR 39; PROTEASOME; PROTEIN P62; UBIQUITIN; UNCLASSIFIED DRUG;

AUTOPHAGY; CARDIOMYOPATHY; CELL COMMUNICATION; CELL COMPARTMENTALIZATION; CELL JUNCTION; CHEMICAL PARAMETERS; CYTOSKELETON; HEART DISEASE; HEART MUSCLE; HUMAN; LYSOSOME; MUSCLE CHANNELOPATHY; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; REVIEW; SARCOLEMMA; SARCOMERE; SIGNAL TRANSDUCTION; UBIQUITIN PROTEASOME SYSTEM;

ANIMALS; AUTOPHAGY; CARDIOMYOPATHIES; CHANNELOPATHIES; CYTOSKELETON; HUMANS; LYSOSOMES; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTEOLYSIS; SARCOLEMMA; SARCOMERES; UBIQUITIN;

EID: 84875863304     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.01.005     Document Type: Review

References (118)

1. Portbury A.L., et al. Tearin' up my heart: proteolysis in the cardiac sarcomere. J. Biol. Chem. 2011, 286:9929-9934.
2. Su H., Wang X. The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc. Res. 2010, 85:253-262.
3. Mearini G., et al. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc. Res. 2010, 85:357-366.
4. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
5. Pan Z.Q., et al. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004, 23:1985-1997.
6. Sakata E., et al. Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity. Nat. Struct. Mol. Biol. 2007, 14:167-168.
7. Wei N., et al. The COP9 signalosome: more than a protease. Trends Biochem. Sci. 2008, 33:592-600.
8. Sharon M., et al. Symmetrical modularity of the COP9 signalosome complex suggests its multifunctionality. Structure 2009, 17:31-40.
9. Zhao R., et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J. Clin. Invest. 2011, 121:851-865.
10. Hunter C., et al. Subunit 3 of the COP9 signalosome is poised to facilitate communication between the extracellular matrix and the nucleus through the muscle-specific β1D integrin. Cell Commun. Adhes. 2008, 15:247-260.
11. Johansen T., Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011, 7:279-296.
12. Klionsky D.J., et al. A unified nomenclature for yeast autophagy-related genes. Dev. Cell 2003, 5:539-545.
13. Kirkin V., et al. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
14. Zheng Q., et al. Proteasome malfunction activates macroautophagy in the heart. Am. J. Cardiovasc. Dis. 2011, 1:214-226.
15. Liu J., et al. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J. Mol. Cell. Cardiol. 2006, 40:451-454.
16. Tannous P., et al. Autophagy is an adaptive response in desmin-related cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9745-9750.
17. Zheng Q., et al. Autophagy and p62 in cardiac proteinopathy. Circ. Res. 2011, 109:296-308.
18. Frank D., Frey N. Cardiac Z-disc signaling network. J. Biol. Chem. 2011, 286:9897-9904.
19. Centner T., et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 2001, 306:717-726.
20. Kedar V., et al. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:18135-18140.
21. Witt S.H., et al. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. J. Mol. Biol. 2005, 350:713-722.
22. Spencer J.A., et al. Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J. Cell Biol. 2000, 150:771-784.
23. Witt C.C., et al. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 2008, 27:350-360.
24. Willis M.S., et al. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ. Res. 2007, 100:456-459.
25. Willis M.S., et al. Muscle ring finger 1 mediates cardiac atrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H997-H1006.
26. Fielitz J., et al. Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4377-4382.
27. Oertel M.F., et al. Alpha-B-crystallin expression in tissues derived from different species in different age groups. Ophthalmologica 2000, 214:13-23.
28. Bennardini F., et al. Alpha B-crystallin in cardiac tissue. Association with actin and desmin filaments. Circ. Res. 1992, 71:288-294.
29. Vicart P., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat. Genet. 1998, 20:92-95.
30. Wang X., et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ. Res. 2001, 89:84-91.
31. Lin D.I., et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol. Cell 2006, 24:355-366.
32. Li H.H., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 2004, 114:1058-1071.
33. Molkentin J.D., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
34. Usui S., et al. Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-κB. Circ. Res. 2011, 109:161-171.
35. Richard P., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003, 107:2227-2232.
36. Carrier L. Cardiac myosin-binding protein C in the heart. Arch. Mal. Coeur Vaiss. 2007, 100:238-243.
37. Greenberg C.C., et al. Krp1 (Sarcosin) promotes lateral fusion of myofibril assembly intermediates in cultured mouse cardiomyocytes. Exp. Cell Res. 2008, 314:1177-1191.
38. Lange S., et al. Obscurin and KCTD6 regulate cullin-dependent small ankyrin-1 (sAnk1.5) protein turnover. Mol. Biol. Cell 2012, 23:2490-2504.
39. Su H., et al. Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice. Circ. Res. 2011, 108:40-50.
40. Miller R.K., et al. CSN-5, a component of the COP9 signalosome complex, regulates the levels of UNC-96 and UNC-98, two components of M-lines in Caenorhabditis elegans muscle. Mol. Biol. Cell 2009, 20:3608-3616.
41. Samarel A.M. Costameres, focal adhesions, and cardiomyocyte mechanotransduction. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2291-H2301.
42. Rafiq K., et al. Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J. Biol. Chem. 2006, 281:19781-19792.
43. Rafiq K., et al. c-Cbl ubiquitin ligase regulates focal adhesion protein turnover and myofibril degeneration induced by neutrophil protease cathepsin G. J. Biol. Chem. 2012, 287:5327-5339.
44. Goldenberg I., Moss A.J. Long QT syndrome. J. Am. Coll. Cardiol. 2008, 51:2291-2300.
45. Benito B., et al. Brugada syndrome. Prog. Cardiovasc. Dis. 2008, 51:1-22.
46. Amin A.S., et al. Cardiac sodium channelopathies. Pflugers Arch. 2010, 460:223-237.
47. van Bemmelen M.X., et al. Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ. Res. 2004, 95:284-291.
48. Jespersen T., et al. The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4/Nedd4-like family. Cardiovasc. Res. 2007, 74:64-74.
49. Rougier J.S., et al. Ubiquitylation and SUMOylation of cardiac ion channels. J. Cardiovasc. Pharmacol. 2010, 56:22-28.
50. 2+ channel activity through protein-protein interactions. J. Mol. Cell. Cardiol. 2006, 40:562-569.
51. Sheikh F., et al. Cell-cell connection to cardiac disease. Trends Cardiovasc. Med. 2009, 19:182-190.
52. Severs N.J., et al. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc. Res. 2008, 80:9-19.
53. Hilenski L.L., et al. Immunolocalization of ubiquitin conjugates at Z-bands and intercalated discs of rat cardiomyocytes in vitro and in vivo. J. Histochem. Cytochem. 1992, 40:1037-1042.
54. Nepomnyashchikh L.M., et al. Focal degradation of cytoplasmic organelles in cardiomyocytes during regenerative and plastic myocardial insufficiency. Bull. Exp. Biol. Med. 2000, 130:1190-1195.
55. Lange S., et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005, 308:1599-1603.
56. Hirschy A., et al. Stabilised β-catenin in postnatal ventricular myocardium leads to dilated cardiomyopathy and premature death. Basic Res. Cardiol. 2010, 105:597-608.
57. Balasubramanian S., et al. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell. Cardiol. 2006, 41:669-679.
58. Nelson W.J., Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
59. Mahmoodzadeh S., et al. Estrogen receptor α up-regulation and redistribution in human heart failure. FASEB J. 2006, 20:926-934.
60. Masuelli L., et al. β-Catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts. Cardiovasc. Res. 2003, 60:376-387.
61. Chen X., et al. The β-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol. Cell. Biol. 2006, 26:4462-4473.
62. Wu G., et al. Structure of a β-TrCP1-Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCF(β-TrCP1) ubiquitin ligase. Mol. Cell 2003, 11:1445-1456.
63. Su V., Lau A.F. Ubiquitination, intracellular trafficking, and degradation of connexins. Arch. Biochem. Biophys. 2012, 524:16-22.
64. Li X., et al. A novel connexin43-interacting protein, CIP75, which belongs to the UbL-UBA protein family, regulates the turnover of connexin 43. J. Biol. Chem. 2008, 283:5748-5759.
65. Kostin S., et al. Gap junction remodeling and altered connexin 43 expression in the failing human heart. Mol. Cell. Biochem. 2003, 242:135-144.
66. Kitamura H., et al. Correlation of connexin43 expression and late ventricular potentials in nonischemic dilated cardiomyopathy. Circ. J. 2003, 67:1017-1021.
67. Chen X., Zhang Y. Myocardial Cx43 expression in the cases of sudden death due to dilated cardiomyopathy. Forensic Sci. Int. 2006, 162:170-173.
68. Gutstein D.E., et al. Heterogeneous expression of Gap junction channels in the heart leads to conduction defects and ventricular dysfunction. Circulation 2001, 104:1194-1199.
69. Eckardt D., et al. Cardiomyocyte-restricted deletion of connexin 43 during mouse development. J. Mol. Cell. Cardiol. 2006, 41:963-971.
70. Lin H., et al. Remodeling of connexin 43 in the diabetic rat heart. Mol. Cell. Biochem. 2006, 290:69-78.
71. Laing J.G., et al. Proteolysis of connexin 43-containing gap junctions in normal and heat-stressed cardiac myocytes. Cardiovasc. Res. 1998, 38:711-718.
72. Leykauf K., et al. Ubiquitin protein ligase Nedd4 binds to connexin 43 by a phosphorylation-modulated process. J. Cell Sci. 2006, 119:3634-3642.
73. Pines J., Lindon C. Proteolysis: anytime, any place, anywhere?. Nat. Cell Biol. 2005, 7:731-735.
74. Muratani M., Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 2003, 4:192-201.
75. Toth A., et al. Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase. J. Biol. Chem. 2006, 281:3679-3689.
76. Song H., et al. Increased p53 protein expression in human failing myocardium. J. Heart Lung Transplant. 1999, 18:744-749.
77. Sano M., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
78. Schuster K., et al. MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol. Cancer Res. 2007, 5:403-412.
79. Pei D., et al. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012, 3:228-235.
80. Grier J.D., et al. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol. Cell. Biol. 2006, 26:192-198.
81. Xiong S., et al. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 2007, 115:2925-2930.
82. Kachaeva E.V., Shenkman B.S. Various jobs of proteolytic enzymes in skeletal muscle during unloading: facts and speculations. J. Biomed. Biotechnol. 2012, 2012:493618.
83. Akazawa H., Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ. Res. 2003, 92:1079-1088.
84. Parnaik V.K., et al. Lamins, laminopathies and disease mechanisms: possible role for proteasomal degradation of key regulatory proteins. J. Biosci. 2011, 36:471-479.
85. Chen C.Y., et al. Accumulation of the inner nuclear envelope protein Sun1 is pathogenic in progeric and dystrophic laminopathies. Cell 2012, 149:565-577.
86. Bonne G., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 1999, 21:285-288.
87. Fatkin D., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 1999, 341:1715-1724.
88. Herrmann J., et al. The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc. Res. 2004, 61:11-21.
89. Meiners S., et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008, 51:302-308.
90. Sarikas A., et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc. Res. 2005, 66:33-44.
91. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22:304-311.
92. Bao J., et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H2612-H2618.
93. Eddins M.J., et al. Targeting the ubiquitin E3 ligase MuRF1 to inhibit muscle atrophy. Cell Biochem. Biophys. 2011, 60:113-118.
94. Petiot A., et al. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 2000, 275:992-998.
95. Pattingre S., et al. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008, 90:313-323.
96. +-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem. 1991, 266:17707-17712.
97. Mizushima N., et al. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
98. Mizushima N., et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 2004, 15:1101-1111.
99. Hariharan N., et al. Oxidative stress stimulates autophagic flux during ischemia/reperfusion. Antioxid. Redox Signal. 2011, 14:2179-2190.
100. Lindsten K., et al. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 2003, 21:897-902.
101. Kumarapeli A.R., et al. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 2005, 19:2051-2053.
102. Tsirigotis M., et al. Analysis of ubiquitination in vivo using a transgenic mouse model. Biotechniques 2001, 31:120-126. 128, 130.
103. Li J., et al. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J. Clin. Invest. 2011, 121:3689-3700.
104. Tian Z., et al. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ. Res. 2012, 111:532-542.
105. Stansfield W.E., et al. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H645-H650.
106. Charaf E., et al. Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr. Cardiol. Rev. 2009, 5:228-236.
107. LoConte N.K., et al. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother. Pharmacol. 2008, 63:109-115.
108. Musil L.S., et al. Regulation of connexin degradation as a mechanism to increase gap junction assembly and function. J. Biol. Chem. 2000, 275:25207-25215.
109. Voortman J., Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006, 6:129.
110. Doll D., et al. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem. Biophys. Res. Commun. 2007, 353:436-442.
111. Okada K., et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004, 110:705-712.
112. Zolk O., et al. The ubiquitin-proteasome system: focus on the heart. Cardiovasc. Res. 2006, 70:410-421.
113. Nakai A., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 2007, 13:619-624.
114. Cao D.J., et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4123-4128.
115. Kong Y., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
116. Nair S., Ren J. Autophagy and cardiovascular aging: lesson learned from rapamycin. Cell Cycle 2012, 11:2092-2099.
117. Bahro M., Pfeifer U. Short-term stimulation by propranolol and verapamil of cardiac cellular autophagy. J. Mol. Cell. Cardiol. 1987, 19:1169-1178.
118. Jin Y., et al. Role of autophagy in myocardial reperfusion injury. Front. Biosci. (Elite Ed.) 2010, 2:1147-1153.